Jason Ehrlich is listed as an executive officer and director on 1 SEC Form D filing by 1 issuer in Jun 2026: Ollin Biosciences, Inc. (Austin, TX — biotechnology — 2026; $156.2M reported sold to 32 investors).
What this means One deal on file with the SEC, filed Jun 2026. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Alaa Halawa (1 shared filing), Cariad Chester (1 shared filing), Fred Cohen (1 shared filing), Jason Coloma (1 shared filing), Paul Berns (1 shared filing) and 1 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Jason. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 1 bankruptcy case matching the name listed in Key records below.
What this means 1 record came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 1 public filing for Jason Ehrlich and found 2 differences: Form D filed 41 days after the first sale; Same name, different state: "Jason Ehrlich" (GA) is a separate record.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.